MOUNTAIN VIEW, Calif.—Toxicogenomics company Iconix Biosciences announced last month it is co-developing, along with Santa Clara, Calif.-based microarray company Affymetrix, a toxicogenomics solution that improves researchers' understanding of safety issues associated with new drug candidates and other compounds.
Dubbed the ToxFX Analysis Suite, the new offering combines Iconix's automated analysis capabilities with Affymetrix's GeneChip arrays, providing detailed information on a drug candidate's toxicological liabilities and pharmacological properties. This will reportedly help scientists prioritize drug candidates and make preclinical development decisions faster than ever before.
Just how fast? According to Dr. Kurt Jarnagin, vice president of new technology for Iconix, experiments on drug candidates that would have generated toxicogenomics data in a matter of weeks or months can now be completed within a few days.
The ToxFX Analysis Suite can do this in part because it offers the "distilled toxicogenomic experience" of scientists at Iconix and puts data in context with the company's DrugMatrix reference data set, notes Dr. Don Halbert, executive vice president of research and development at Iconix. "We have consistently heard from the toxicology community that analysis of the data is the single largest barrier to applying toxicogenomics as a standard screening tool in drug development programs," he adds.
"Drug discovery scientists are going to be able to get information that they couldn't get before, in a very affordable manner," Jarnagin says. "They are going to be able to look at candidate compounds and...compare those to compounds that they understand well. They will now be able to give reports to project teams with immediately actionable items."